END TREATMENT RESPONSE OF SOFOSBUVIR (SOVALDI) PLUS RIBAVIRIN IN HEPATITIS C PATIENT GENOTYPE 3 AT GASTROENTEROLOGY AND HEPATALOGY UNIT LADY READING HOSPITAL PESHAWAR

×

Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in _menu_load_objects() (line 579 of /home2/kjmscomp/public_html/old/includes/menu.inc).

Abstract

ABSTRACT
Objective: To determine the end Treatment Response (ETR) rate in HCV genotype 3 treated with Sofosbuvir and Ribavirin.
Material and Method: This study was done at HEPATITIS CLINIC PGMI LADY READING HOSPITAL PESHAWARfrom
September 2014 to JUNE 2016. Prior approvalfor this research was taken from ethical committee of lady READING
HOSPITAL PESHAWAR.
A total of 335 patients were selected after properly applying inclusion and exclusion criteria.All patients received Sofosbuvir
(SOVALDI) 400 mg and weight based ribavirin for a period of six months.All patients were fallowed with Full
Blood Count and LFT’s monthly and PCR at week 4,12 and 24.
Results: In this study total of 335 patients were enrolled.There were 184 male and 151 female. 96.4% of males and
96.68 % of the females achieved ETR. Of total, 187 patients were treatment naïve and 180 patients (96.84%) achieved
ETR. The remaining 148 were treatment experienced and 140(92.6%)achieved ETR.
Conclusion: The combination of sofosbuvir and Ribavirin has high ETR rates in both genderas well as in treatment

Authors: 
Abbas Khan Khattak
Muhammad Arif Afridi
Abbas Masood
Hashmatullah Khan,
Kamran Hassan,
Amir Ghafoor Khan
Journal Issue: 

PDF